Even in the face of a pandemic, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) continues to save millions of lives as a leader in the global response to the world’s two deadliest infectious diseases – HIV and TB. As a key implementing agency of PEPFAR, CDC is at the forefront of these global efforts to treat and prevent these diseases. In fact, as of September 30, 2020, as a part of PEPFAR, CDC supported antiretroviral treatment for 40 percent of all people on HIV treatment worldwide.
CDC plays a unique role, bringing scientific know-how and on-the-ground expertise to bring about significant impact in the fight against these diseases. Just last year, our efforts accounted for more than 50 percent of all key PEPFAR outcomes to treat and prevent HIV and TB.
Antiretroviral Treatment for Men, Women, and Children**
PEPFAR: 17.2 Million
CDC: 10.5 Million
Voluntary Medical Male Circumcisions (VMMC)****
PEPFAR: 25.3 Million
CDC: 13 Million
People Who Received a Positive HIV Test Result***
PEPFAR: 2.7 Million
CDC: 1.6 Million
HIV-Positive Persons Screened in Care for Tuberculosis***
PEPFAR: 13.6 Million
CDC: 8.1 Million
Antiretroviral Treatment to Prevent Mother-to-child Transmission***
*Other USG agencies may have also contributed to some of these achievements **As of Sept 30, 2020 ***FY2020 ****Cumulative through Sept 30, 2020
Over a ten-day period, CDC and photo documentarian Thom Pierce traveled to the epicenter of the global HIV epidemic in South Africa to capture the faces and stories of the individuals at the forefront of CDC’s global response against this epidemic. These are their voices.
We have a small window of opportunity to turn the corner on this epidemic. That's why we are driving harder and smarter to achieve epidemic control. Millions of lives are at stake.
CDC is at the forefront of efforts to get life-saving treatment to millions of people living with HIV around the world. As of September 30, 2020, as a part of PEPFAR, CDC supported antiretroviral treatment for 10.5 million people living with HIV – 40 % of all people on treatment worldwide.
“I’m glad I decided to do it. I feel like I'm doing something positive for my health. It's the best decision I could’ve made!”
VMMC has been shown to reduce a man’s risk of acquiring HIV by up to 60 percent. To date, as of September 30, 2020, CDC has supported VMMC procedures for 13 million men in Southern and Eastern Africa – just over half (51%) of all VMMC procedures supported by PEPFAR.
Helping people with HIV know their status and start immediately on treatment allows them to live longer, healthier lives and interrupts the spread of HIV. In 2020, CDC helped 1.6 million people learn their HIV-positive status, nearly 60 % (59%) of all new HIV diagnoses identified through PEPFAR.
We’re not just talking about HIV and TB integration; we’re making it happen!
I think about how we have our medicines now and how we are doing well, but how we all could have perished.
TB is the top killer worldwide of people living with HIV, whose weakened immune systems make them highly susceptible to becoming ill with TB. As of September 30, 2020, CDC supported TB screenings for 8.1 million people with HIV – nearly 60% (59%) of all people with HIV screened for TB through PEPFAR.
Increasing the number of pregnant women on life-saving HIV treatment helps mothers live longer, healthier lives and helps eliminate new infections among their children. In 2020, CDC supported treatment for 483,000 HIV-positive, pregnant women to reduce the risk of mother-to-child transmission – approximately 60% (61%) of all pregnant women who received HIV treatment through PEPFAR.
Visit our “Faces from the Frontlines” gallery and view the video feature below to learn more about those at the forefront of CDC’s global response to HIV and TB. Highlighting their innovations and tireless efforts, these images and stories offer a snapshot into the work CDC and PEPFAR are leading around the world.
Since 2003, CDC and other PEPFAR implementing partners have helped save more than 20 million lives. Worldwide, we’ve witnessed resilience with experts balancing HIV work with competing priorities of the COVID-19 response and yet finding innovative ways to protect the public’s health. While we’ve made great progress, we urgently need to do more. We cannot stop now. Continuing this momentum is critical to controlling and ultimately ending the global HIV and TB epidemics.